 Jonathan Port
Concepts (196)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| RNA-Binding Proteins | 8 | 2010 | 362 | 1.260 |
Why?
| | Heterogeneous-Nuclear Ribonucleoprotein D | 5 | 2010 | 8 | 1.180 |
Why?
| | Antigens, Surface | 5 | 2010 | 151 | 1.180 |
Why?
| | RNA, Messenger | 12 | 2015 | 2574 | 1.080 |
Why?
| | Receptors, Adrenergic, beta | 8 | 2004 | 133 | 1.030 |
Why?
| | MicroRNAs | 5 | 2015 | 607 | 0.770 |
Why?
| | Receptors, Adrenergic, beta-1 | 8 | 2015 | 53 | 0.580 |
Why?
| | RNA Stability | 3 | 2004 | 93 | 0.570 |
Why?
| | Myocardium | 10 | 2011 | 926 | 0.550 |
Why?
| | Adrenergic beta-Antagonists | 6 | 2015 | 293 | 0.450 |
Why?
| | Cardiomyopathy, Dilated | 5 | 2015 | 352 | 0.420 |
Why?
| | 3' Untranslated Regions | 4 | 2010 | 136 | 0.370 |
Why?
| | Poly(A)-Binding Proteins | 1 | 2010 | 5 | 0.370 |
Why?
| | Fluorescence Resonance Energy Transfer | 2 | 2010 | 176 | 0.340 |
Why?
| | Multiprotein Complexes | 1 | 2010 | 145 | 0.330 |
Why?
| | Propanolamines | 4 | 2013 | 94 | 0.330 |
Why?
| | Gene Expression Regulation | 5 | 2011 | 2353 | 0.310 |
Why?
| | Cricetinae | 5 | 2010 | 260 | 0.310 |
Why?
| | ELAV Proteins | 5 | 2010 | 17 | 0.310 |
Why?
| | ELAV-Like Protein 1 | 5 | 2010 | 20 | 0.300 |
Why?
| | Protein Interaction Mapping | 1 | 2007 | 102 | 0.280 |
Why?
| | Myocardial Ischemia | 1 | 2008 | 237 | 0.270 |
Why?
| | Polymorphism, Genetic | 4 | 2013 | 621 | 0.270 |
Why?
| | Heart Failure | 9 | 2013 | 1963 | 0.250 |
Why?
| | Signal Transduction | 9 | 2011 | 4541 | 0.240 |
Why?
| | Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 2 | 2004 | 9 | 0.240 |
Why?
| | Myocardial Infarction | 1 | 2011 | 931 | 0.240 |
Why?
| | Anisomycin | 1 | 2004 | 4 | 0.240 |
Why?
| | Nucleic Acid Synthesis Inhibitors | 1 | 2004 | 18 | 0.230 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2004 | 114 | 0.220 |
Why?
| | Globins | 1 | 2002 | 22 | 0.200 |
Why?
| | Enzyme Activation | 1 | 2004 | 793 | 0.200 |
Why?
| | Animals | 16 | 2011 | 32102 | 0.190 |
Why?
| | Cell Line | 5 | 2010 | 2651 | 0.190 |
Why?
| | Protein Binding | 5 | 2010 | 1917 | 0.190 |
Why?
| | Down-Regulation | 3 | 2015 | 601 | 0.180 |
Why?
| | Receptors, Adrenergic | 1 | 2000 | 36 | 0.170 |
Why?
| | Heart Ventricles | 3 | 2015 | 712 | 0.170 |
Why?
| | Cardiovascular Diseases | 1 | 2010 | 1724 | 0.170 |
Why?
| | Models, Biological | 2 | 2001 | 1646 | 0.150 |
Why?
| | Carbazoles | 2 | 2001 | 80 | 0.140 |
Why?
| | Gene Expression Profiling | 4 | 2015 | 1536 | 0.140 |
Why?
| | Heterogeneous-Nuclear Ribonucleoproteins | 2 | 2004 | 19 | 0.100 |
Why?
| | Base Sequence | 4 | 2002 | 2114 | 0.100 |
Why?
| | Recombinant Proteins | 3 | 2002 | 1243 | 0.100 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 1992 | 28 | 0.100 |
Why?
| | Lung Neoplasms | 2 | 2004 | 2207 | 0.100 |
Why?
| | Protein Transport | 2 | 2010 | 400 | 0.090 |
Why?
| | Software | 1 | 2015 | 541 | 0.090 |
Why?
| | Half-Life | 2 | 2002 | 145 | 0.090 |
Why?
| | Mice | 6 | 2011 | 15052 | 0.090 |
Why?
| | Vasodilator Agents | 1 | 1992 | 308 | 0.090 |
Why?
| | Receptors, Adrenergic, alpha-2 | 1 | 2009 | 15 | 0.090 |
Why?
| | Gene Expression | 1 | 2015 | 1435 | 0.080 |
Why?
| | Adrenergic beta-Agonists | 2 | 2001 | 129 | 0.080 |
Why?
| | Mice, Transgenic | 3 | 2011 | 1970 | 0.080 |
Why?
| | Protein Multimerization | 1 | 2010 | 160 | 0.080 |
Why?
| | Atrial Fibrillation | 1 | 2013 | 325 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 930 | 0.080 |
Why?
| | Norepinephrine | 1 | 2009 | 207 | 0.080 |
Why?
| | Humans | 19 | 2015 | 115587 | 0.080 |
Why?
| | Antihypertensive Agents | 1 | 1992 | 432 | 0.080 |
Why?
| | Transfection | 2 | 2002 | 866 | 0.080 |
Why?
| | Heart Function Tests | 1 | 2008 | 59 | 0.080 |
Why?
| | Molecular Sequence Data | 4 | 2007 | 2790 | 0.070 |
Why?
| | Phenotype | 1 | 2015 | 2829 | 0.070 |
Why?
| | Cytoplasm | 1 | 2007 | 255 | 0.070 |
Why?
| | Ultraviolet Rays | 2 | 2002 | 372 | 0.070 |
Why?
| | Animals, Newborn | 1 | 2008 | 780 | 0.070 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2007 | 158 | 0.060 |
Why?
| | GTP-Binding Proteins | 2 | 1996 | 142 | 0.060 |
Why?
| | Ventricular Function, Left | 1 | 2008 | 467 | 0.060 |
Why?
| | Biological Products | 1 | 2007 | 172 | 0.060 |
Why?
| | Heterogeneous Nuclear Ribonucleoprotein A1 | 2 | 2004 | 6 | 0.060 |
Why?
| | DNA Primers | 3 | 2011 | 514 | 0.060 |
Why?
| | Cell Nucleus | 1 | 2007 | 553 | 0.060 |
Why?
| | Butadienes | 1 | 2004 | 31 | 0.060 |
Why?
| | Anthracenes | 1 | 2004 | 28 | 0.060 |
Why?
| | Clinical Trials as Topic | 2 | 2015 | 941 | 0.060 |
Why?
| | Flavonoids | 1 | 2004 | 68 | 0.060 |
Why?
| | RNA Precursors | 1 | 2004 | 136 | 0.060 |
Why?
| | Nitriles | 1 | 2004 | 152 | 0.050 |
Why?
| | RNA Splicing | 1 | 2004 | 244 | 0.050 |
Why?
| | Rats | 2 | 2008 | 5034 | 0.050 |
Why?
| | Imidazoles | 1 | 2004 | 217 | 0.050 |
Why?
| | Base Composition | 1 | 2002 | 76 | 0.050 |
Why?
| | Uracil | 1 | 2002 | 31 | 0.050 |
Why?
| | Regulatory Sequences, Ribonucleic Acid | 1 | 2002 | 18 | 0.050 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2004 | 332 | 0.050 |
Why?
| | Xamoterol | 1 | 2001 | 2 | 0.050 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2002 | 74 | 0.050 |
Why?
| | Mice, Inbred C57BL | 1 | 2011 | 4773 | 0.050 |
Why?
| | Protein Kinase Inhibitors | 1 | 2007 | 790 | 0.050 |
Why?
| | Mice, Inbred BALB C | 2 | 2004 | 1168 | 0.050 |
Why?
| | Male | 10 | 2015 | 55949 | 0.050 |
Why?
| | Hypertrophy | 1 | 2001 | 110 | 0.050 |
Why?
| | Amino Acid Sequence | 2 | 2007 | 2000 | 0.050 |
Why?
| | Isoproterenol | 2 | 1998 | 110 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2004 | 757 | 0.050 |
Why?
| | Pyridines | 1 | 2004 | 425 | 0.050 |
Why?
| | Cells, Cultured | 1 | 2008 | 3914 | 0.050 |
Why?
| | Adenine | 1 | 2002 | 221 | 0.040 |
Why?
| | Precipitin Tests | 1 | 2000 | 90 | 0.040 |
Why?
| | Chromatography, Affinity | 1 | 2000 | 83 | 0.040 |
Why?
| | Computational Biology | 2 | 2015 | 536 | 0.040 |
Why?
| | Ribonucleoproteins | 1 | 2000 | 87 | 0.040 |
Why?
| | Cycloheximide | 1 | 1998 | 56 | 0.040 |
Why?
| | Protein Synthesis Inhibitors | 1 | 1998 | 44 | 0.040 |
Why?
| | Adenylyl Cyclases | 2 | 1995 | 84 | 0.040 |
Why?
| | Drug Stability | 1 | 1998 | 152 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2000 | 850 | 0.040 |
Why?
| | Receptors, Angiotensin | 1 | 1997 | 10 | 0.040 |
Why?
| | Protein Biosynthesis | 1 | 1998 | 390 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2000 | 645 | 0.030 |
Why?
| | Age Factors | 2 | 2015 | 2907 | 0.030 |
Why?
| | Polyribosomes | 1 | 1996 | 23 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2000 | 1642 | 0.030 |
Why?
| | Brain Death | 1 | 1995 | 32 | 0.030 |
Why?
| | Catecholamines | 1 | 1995 | 97 | 0.030 |
Why?
| | Muscle, Smooth | 1 | 1996 | 150 | 0.030 |
Why?
| | Decision Trees | 1 | 2015 | 81 | 0.030 |
Why?
| | Computer Graphics | 1 | 2015 | 43 | 0.030 |
Why?
| | Myocardial Contraction | 1 | 1995 | 316 | 0.030 |
Why?
| | Data Interpretation, Statistical | 1 | 2015 | 324 | 0.030 |
Why?
| | Echocardiography | 2 | 2011 | 558 | 0.030 |
Why?
| | Iodocyanopindolol | 1 | 1992 | 12 | 0.030 |
Why?
| | Pindolol | 1 | 1992 | 16 | 0.030 |
Why?
| | Culture Techniques | 1 | 1992 | 80 | 0.030 |
Why?
| | Stroke Volume | 1 | 2015 | 509 | 0.030 |
Why?
| | Apoptosis | 1 | 2001 | 2377 | 0.030 |
Why?
| | Ventricular Dysfunction, Left | 1 | 1995 | 366 | 0.020 |
Why?
| | Models, Genetic | 1 | 2015 | 570 | 0.020 |
Why?
| | Chronic Disease | 1 | 1998 | 1598 | 0.020 |
Why?
| | Binding, Competitive | 1 | 1992 | 200 | 0.020 |
Why?
| | Time Factors | 1 | 2002 | 6165 | 0.020 |
Why?
| | Female | 7 | 2015 | 59913 | 0.020 |
Why?
| | Precision Medicine | 1 | 2015 | 344 | 0.020 |
Why?
| | Cyclic AMP | 1 | 1992 | 227 | 0.020 |
Why?
| | Heart Transplantation | 2 | 1993 | 671 | 0.020 |
Why?
| | Glycine | 1 | 2011 | 156 | 0.020 |
Why?
| | Up-Regulation | 1 | 1993 | 820 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2011 | 317 | 0.020 |
Why?
| | Arginine | 1 | 2011 | 241 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 1736 | 0.020 |
Why?
| | Lymphocytes | 1 | 1992 | 344 | 0.020 |
Why?
| | Heart | 1 | 1993 | 608 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2011 | 746 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2011 | 1227 | 0.020 |
Why?
| | Spodoptera | 1 | 2007 | 37 | 0.020 |
Why?
| | Algorithms | 1 | 2015 | 1490 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2015 | 1918 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2007 | 357 | 0.020 |
Why?
| | Rats, Wistar | 1 | 2007 | 368 | 0.020 |
Why?
| | Middle Aged | 3 | 2015 | 26999 | 0.020 |
Why?
| | Receptors, Adrenergic, beta-2 | 2 | 1997 | 42 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2007 | 804 | 0.020 |
Why?
| | Butylated Hydroxytoluene | 1 | 2004 | 32 | 0.020 |
Why?
| | Serine-Arginine Splicing Factors | 1 | 2004 | 19 | 0.020 |
Why?
| | Aged | 2 | 2015 | 19251 | 0.020 |
Why?
| | Hyaluronan Receptors | 1 | 2004 | 91 | 0.010 |
Why?
| | Hyperplasia | 1 | 2004 | 166 | 0.010 |
Why?
| | Reference Values | 2 | 1997 | 744 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2004 | 339 | 0.010 |
Why?
| | Phosphorylation | 1 | 2007 | 1571 | 0.010 |
Why?
| | Alternative Splicing | 1 | 2004 | 187 | 0.010 |
Why?
| | Hippocampus | 1 | 2007 | 709 | 0.010 |
Why?
| | Models, Molecular | 1 | 2007 | 1390 | 0.010 |
Why?
| | Infant | 1 | 2015 | 7979 | 0.010 |
Why?
| | Polymerase Chain Reaction | 2 | 1997 | 1000 | 0.010 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2004 | 314 | 0.010 |
Why?
| | Peptides | 1 | 2007 | 864 | 0.010 |
Why?
| | Prospective Studies | 1 | 2013 | 6264 | 0.010 |
Why?
| | Child, Preschool | 1 | 2015 | 9133 | 0.010 |
Why?
| | Islets of Langerhans | 1 | 2007 | 729 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2004 | 1178 | 0.010 |
Why?
| | Young Adult | 1 | 2015 | 10470 | 0.010 |
Why?
| | Adult | 3 | 2015 | 30718 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2013 | 9159 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2009 | 6417 | 0.010 |
Why?
| | Insulin | 1 | 2007 | 2082 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2004 | 2194 | 0.010 |
Why?
| | Adolescent | 1 | 2015 | 17889 | 0.010 |
Why?
| | Receptor, Angiotensin, Type 2 | 1 | 1997 | 8 | 0.010 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 1997 | 21 | 0.010 |
Why?
| | Radioligand Assay | 1 | 1997 | 45 | 0.010 |
Why?
| | Angiotensin II | 1 | 1997 | 91 | 0.010 |
Why?
| | Child | 1 | 2015 | 18488 | 0.010 |
Why?
| | Antisense Elements (Genetics) | 1 | 1993 | 5 | 0.010 |
Why?
| | Heart-Lung Transplantation | 1 | 1993 | 10 | 0.010 |
Why?
| | Denervation | 1 | 1993 | 19 | 0.010 |
Why?
| | Kinetics | 1 | 1997 | 1569 | 0.010 |
Why?
| | Cell Membrane | 1 | 1997 | 683 | 0.010 |
Why?
| | Tissue Donors | 1 | 1995 | 331 | 0.010 |
Why?
| | Reoperation | 1 | 1993 | 525 | 0.010 |
Why?
| | Case-Control Studies | 1 | 1995 | 3022 | 0.000 |
Why?
| | DNA | 1 | 1993 | 1356 | 0.000 |
Why?
|
|
Port's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|